Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis by unknown
RESEARCH Open Access
Siponimod (BAF312) prevents synaptic
neurodegeneration in experimental
multiple sclerosis
Antonietta Gentile1,2†, Alessandra Musella1†, Silvia Bullitta1, Diego Fresegna1,2, Francesca De Vito1,2,
Roberta Fantozzi3, Eleonora Piras4, Francesca Gargano4, Giovanna Borsellino4, Luca Battistini4, Anna Schubart5,
Georgia Mandolesi1*† and Diego Centonze2,3†
Abstract
Background: Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune
encephalomyelitis (EAE), highlighted an inflammation-dependent synaptopathy at the basis of the neurodegenerative
damage causing irreversible disability in these disorders. This synaptopathy is characterized by an imbalance between
glutamatergic and GABAergic transmission and has been proposed to be a potential therapeutic target.
Siponimod (BAF312), a selective sphingosine 1-phosphate1,5 receptor modulator, is currently under investigation in a
clinical trial in secondary progressive MS patients. We investigated whether siponimod, in addition to its peripheral
immune modulation, may exert direct neuroprotective effects in the central nervous system (CNS) of mice with chronic
progressive EAE.
Methods: Minipumps allowing continuous intracerebroventricular (icv) infusion of siponimod for 4 weeks were
implanted into C57BL/6 mice subjected to MOG35-55-induced EAE. Electrophysiology, immunohistochemistry, western
blot, qPCR experiments, and peripheral lymphocyte counts were performed. In addition, the effect of siponimod on
activated microglia was assessed in vitro to confirm the direct effect of the drug on CNS-resident immune cells.
Results: Siponimod administration (0.45 μg/day) induced a significant beneficial effect on EAE clinical scores with
minimal effect on peripheral lymphocyte counts. Siponimod rescued defective GABAergic transmission in the striatum
of EAE, without correcting the EAE-induced alterations of glutamatergic transmission. We observed a significant
attenuation of astrogliosis and microgliosis together with reduced lymphocyte infiltration in the striatum of EAE mice
treated with siponimod. Interestingly, siponimod reduced the release of IL-6 and RANTES from activated microglial cells
in vitro, which might explain the reduced lymphocyte infiltration. Furthermore, the loss of parvalbumin-positive (PV+)
GABAergic interneurons typical of EAE brains was rescued by siponimod treatment, providing a plausible explanation
of the selective effects of this drug on inhibitory synaptic transmission.
Conclusions: Altogether, our results show that siponimod has neuroprotective effects in the CNS of EAE mice,
which are likely independent of its peripheral immune effect, suggesting that this drug could be effective in
limiting neurodegenerative pathological processes in MS.
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Abbreviations: BBB, Blood brain barrier; BDNF, Brain-derived neurotrophic factor; CFA, Complete Freund’s adjuvant;
CNS, Central nervous system; DAB, Diaminobenzidine; DAPI, 4′,6-Diamidino-2-phenylindole; DMSO, Dimethyl sulfoxide;
dpi, Day post-immunization; EAE, Experimental autoimmune encephalomyelitis; GABA, Gamma-amino butyric acid;
GFAP, Glial fibrillary amino acid protein; GM, Gray matter; IBA1, Ionized calcium binding adaptor protein-1;
icv, Intracerebroventricular; IL, Interleukin; MOG, Myelin oligodendrocyte glycoprotein; MRM, Multiple reaction
monitoring; MS, Multiple sclerosis; MSN, Medium spiny neuron; PBS, Phosphate buffer solution; PPMS, Primary
progressive MS; PV, Parvalbumin; qPCR, Quantitative-polymerase chain reaction; RANTES, Regulated on activation,
normal T cell expressed and secreted; RRMS, Relapsing-remitting MS; S1P, Sphingosine-1-phosphate receptor;
sEPSC, Spontaneous excitatory post-synaptic currents; sIPSCs, Spontaneous inhibitory post-synaptic currents;
SPMS, Secondary progressive MS; TBS, Tris buffered solution; TNF, Tumor necrosis factor; WB, Western blot
Background
Multiple sclerosis (MS) is an inflammatory neurodegen-
erative disease of the central nervous system (CNS), af-
fecting young adults. Clinically, two main forms of MS
can be distinguished, the relapsing-remitting (RRMS) and
the progressive, where the latter is described as the grad-
ual progression of clinical disability in a patient either with
a preceding relapsing course (secondary progressive MS
(SPMS)) or without a preceding relapsing course (primary
progressive MS (PPMS)) [1].
Such phenotypic distinction seems to rely on predom-
inance of distinct pathogenic mechanisms that appear
different, though poorly understood, throughout RRMS,
PPMS, and SPMS [2]. In general, although inflammation
has a recognized pivotal role in triggering the cascade of
events leading to both white and gray matter (GM)
damage, anti-inflammatory or immunomodulatory drugs
have been found successful only in RRMS [3], with the re-
cent exception of ocrelizumab, which was found to reduce
disability progression also in PPMS [4]. A forthcoming
challenge is therefore to identify drugs able to interfere
with the mechanisms leading to neurodegeneration in
PPMS and in SPMS.
GM pathology in MS is increasingly recognized to
contribute to the progression of the disease. In fact, GM
damage occurs early in the disease course, is independent
of demyelination, and is associated with neurological and
neuropsychological disability [5]. Several studies in ex-
perimental autoimmune encephalomyelitis (EAE), the
murine model of MS, have underscored an inflammation-
dependent synaptopathy affecting different brain struc-
tures (striatum, hippocampus, cerebellum) and occurring
independently of demyelination [6–10]. In such brain
areas of EAE mice, the excitatory glutamatergic trans-
mission is potentiated, while the GABAergic inhibitory
transmission is reduced: this imbalance in synaptic
transmission leads to excitotoxicity and subsequently to
neurodegeneration [11]. Of note, glutamate receptor an-
tagonists and gamma-amino butyric acid (GABA) agonists
exert beneficial effects in both EAE and MS [12–16]. This
synaptopathy has been proposed as a valuable therapeutic
target [11].
Several drugs are under investigation for their neuropro-
tective effects in progressive MS. In particular, an ongoing
phase-III clinical trial is currently conducted with the
sphingosine-1-phosphate receptor (S1P) modulator,
siponimod (BAF312) [17]. Siponimod is a next-generation
S1P modulator selective for S1P1 and S1P5 that showed
good safety and tolerability in humans. This compound
has recently successfully passed a phase-II clinical trial in
RRMS [18].
Compared to fingolimod, an S1P modulator selective for
S1P1, S1P3, S1P4, and S1P5, the half-life of siponimod is
shorter, allowing recovery of peripheral lymphocyte count
to a normal range within 1 week after treatment cessation.
The risk of bradycardia is mitigated using a dose titration
scheme during treatment initiation [19, 20].
Most of the effects of siponomid are attributed to S1P1
expressed on lymphocytes, thereby preventing lymphocyte
trafficking into the brain, but both S1P1 and S1P5 are
widely expressed in brain-resident cells, like neurons,
microglia, astroglia, and oligodendrocytes [21].
The aim of the present study was therefore to assess
the central effects of siponimod in mice with myelin
oligodendrocyte glycoprotein peptide 35-55 (MOG35-55)-
induced EAE, a model of progressive MS, to provide a




EAE was induced as described previously [7, 20]. Mice
were injected subcutaneously at the flanks with 200 μg
of MOG35-55 emulsion to induce EAE by active
immunization. The emulsion was prepared under ster-
ile conditions using MOG35-55 (85 % purity; Espikem)
in 300 μl of complete Freund’s adjuvant (CFA; Difco)
containing Mycobacterium tuberculosis (8 mg/ml, strain
H37Ra; Difco) and emulsified with phosphate buffer
solution (PBS). All animals were injected with 500 ng
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of pertussis toxin (Sigma) intravenously on the day of
immunization and 2 days later. Control animals received
the same treatment as EAE mice without the immunogen
MOG peptide, including complete CFA and pertussis
toxin (referred to as hereafter as “CFA”). Animals were
scored daily for clinical symptoms of EAE according to
the following scale: 0 = no clinical signs, 1 = flaccid tail,
2 = hindlimb weakness, 3 = hindlimb paresis, 4 = complete
bilateral hindlimb paralysis, and 5 = death due to EAE;
intermediate clinical signs were scored by adding 0.5
[15, 22]. For each animal, the onset day was recorded
as the day post-immunization (dpi) when it showed the
first clinical manifestations.
Experiments were carried out in accordance with In-
ternal Institutional Review Committee, the European Dir-
ective 2010/63/EU and the European Recommendations
526/2007, and the Italian D.Lgs26/2014. All the efforts
were made to minimize the number of animals utilized
and their suffering.
Siponimod formulation for minipump and surgery
Siponimod (Novartis Pharma AG) was dissolved in a
solution containing 10 % Solutol/Kolliphor HS15 (BASF
Pharma Solutions)—final pH range between 6 and 7—at a
final concentration of 2 mg/ml. This preparation allowed
stability of the drug for up to 6 weeks at 37 °C.
One week before immunization, mice were implanted
with subcutaneous osmotic minipumps allowing continu-
ous intracerebroventricular (icv) infusion of either vehicle
or siponimod for 4 weeks (three sets of immunizations)
[8, 22]. Different siponimod dosages were tested: 4.5, 0.45,
and 0.225 μg/day.
T cell absolute count
T cell absolute count was performed on blood samples
kept from the mandibular vein of the mouse.
For the phenotypic characterization of cell populations,
the following antibodies were used: CD8-FITC (Miltenyi
Biotec), CD25-APC (Pharmingen), CD3-PE-Vio770
(Miltenyi Biotec), CD4-APC-Vio770 (Milteny Biotec),
CD45R (B220)-Violblu (Milteny Biotec), NK1.1-PE (Milteny
Biotec).
At predetermined optimal concentrations, 100 μl of
blood was stained by incubation with the antibodies.
Fifty microliters of CountBright Absolute Counting Beads
(Molecular Probes) was added, and, following lysis of red
blood cells, cells were acquired on a CyAn Cytometer
(Beckman Coulter). By comparing the ratio of bead events
to cell events, absolute numbers of cells in the sample
were calculated.
Some experiments were performed by acquiring the
stained blood samples on the CytoFLEX cytometer
(Coulter), equipped with a volumetric sample injection
module, which enables volumetric sampling and provides
absolute cell counts for all samples without the use of
beads.
Determination of siponimod in mouse blood by LC-MS
For quantitative determination, 10 spiked samples from
0.5 up to 10,000 ng/ml were prepared in the same matrix.
Proteins were removed by protein precipitation by adding
an organic solvent mixture. The organic layer was evapo-
rated to dryness, and the residue was re-dissolved in
HPLC buffer B, containing 5 mM ammonium formate.
Aliquots of 2 μl were directly injected on a Agilent
Eclipse Plus, RRHD 2.1 × 50 mm reversed-phase column
with 1.8-μm particles, and kept at 40 °C.
For separation, a linear gradient from 50 to 100 % B
within 1.7 min was used. Solvent A was 0.2 % formic acid
in water and solvent B 0.2 % formic acid in acetonitrile.
The flow was kept at 500 μl/min during the whole cycle.
For detection, the column effluent was guided directly
to the electrospray source of the Agilent 6490 triple
quadrupole MS with parameters optimized for siponi-
mod. Compound and a structure-related internal stand-
ard were detected as their [MH]+ ions with the multiple
reaction monitoring (MRM) transition 517.3→ 159.0,
416.1 for siponimod. For data processing, the compound
to internal standard ratio of the extracted ion chromato-
grams was used.
The calculation was based on a second order fitted
and 1/x weighted calibration curve (r2 = 0.9987). The ac-
curacy of the 10 individually prepared calibration samples
was better than 15 %. The recovery of the compounds was
94.3 % (RSD = 1.3 %). The precision of the control samples
(n = 3), distributed over the whole series, was better than
RSD = 1.8 %. The LOQ for siponimod was found to be
0.5 ng/ml, based on the lowest calibration sample.
Electrophysiology
Mice were killed by cervical dislocation, and corticos-
triatal coronal slices (200 μm) were prepared from fresh
tissue blocks of the brain with the use of a vibratome
[6, 15]. Single slices were then transferred to a record-
ing chamber and submerged in a continuously flowing
oxygenated artificial cerebrospinal fluid (ACSF) (34 °C,
2–3 ml/min) gassed with 95 % O2–5 % CO2. The com-
position of the control ACSF was (in mM) as follows:
126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 2.4
CaCl2, 11 Glucose, 25 NaHCO3. Whole-cell patch clamp
recordings were made with borosilicate glass pipettes
(1.8 mm o.d.; 4–8 MΩ), in voltage-clamp mode, at the
holding potential (HP) of −80 mV. Spontaneous excitatory
and inhibitory post-synaptic currents (EPSCs, IPSCs) were
recorded from medium spiny neurons (MSNs) as in
Centonze et al. [15] and Rossi et al. [6]. Siponimod
(1 μM) was added to the bath solution for 1 h, before re-
cording. Synaptic events were stored by using P-CLAMP
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9.2 (Axon Instruments) and analyzed offline on a personal
computer with Mini Analysis 5.1 (Synaptosoft, Leonia, NJ,
USA) software. Offline analysis was performed on spon-
taneous synaptic events recorded during fixed time epochs
(1–2 min, three to five samplings), sampled every 5 or
10 min. One to six cells per animal were recorded, and
four animals were sacrificed for each experimental group.
Western blot
Animals were killed by cervical dislocation at 24 dpi.
Striata were quickly removed, snap frozen in dry ice, and
homogenized as in Mandolesi et al. [8] and Gentile et al.
[22]. Soon after blocking with 5 % milk in Tris buffered
solution (TBS), the membrane was incubated for 1 h
with mouse anti-β-actin primary antibody (1:20,000; Sigma-
Aldrich) followed by anti-mouse IgG HRP (1:10,000, GE
Healthcare, formerly Amersham Biosciences) secondary
antibody. Immunodetection was performed by ECL re-
agent (Amersham) and membrane was exposed to film
(Amersham). Next, a mouse anti-glial fibrillary amino
acid protein (GFAP, 1:2000, Immunological Science, over
night) primary antibody was used in combination with
anti-mouse IgG HRP (1:4000 for GFAP; GE Healthcare,
formerly Amersham Biosciences) secondary antibody.
Immunodetection was performed as for β-actin. Densito-
metric analysis of bands was performed by NIH ImageJ
software (http://rsb.info.nih.gov/ij/). Western blot (WB)
results are presented as data normalized to control CFA
values.
RNA extraction and quantitative real-time PCR
Striata were dissected in RNAse-free conditions. Total
RNA was extracted according to the standard miRNeasy
Micro kit protocol (Qiagen). Next, 350 ng of total RNA
was reverse-transcribed using High-Capacity cDNA Re-
verse Transcription Kit (Applied Biosystem), and 10 ng
of complementary DNA (cDNA) was amplified with
SensiMix SYBR Hi-Rox Kit (Bioline; Meridian Life Sci-
ence) in triplicate using the Applied Biosystem 7900HT
Fast Real-Time PCR system. Messenger RNA (mRNA)
relative quantification was performed using the compara-
tive cycle threshold (2−ΔΔCt) method. β-actin was used as
endogenous control.
Primer sequences:







For CD3+ mRNA detection, 17.5 ng of the same
cDNA was amplified with SensiMix II Probe (Bioline;
Meridian Life Science) by using TaqMan gene expression
assays (ID Mm00599684_g1 and ID Mm00607939;
Applied Biosystem).
Immunofluorescence and confocal microscopy
Mice from two different immunization experiments were
deeply anesthetized and intracardially perfused with
ice-cold 4 % paraformaldehyde. Brains were post-fixed
for 2 h and equilibrated with 30 % sucrose at least one
overnight. Immunofluorescence was performed as in
Mandolesi et al. [8] and Gentile et al. [22]. The following
primary antibodies were used: rabbit anti-Iba1 (1:750;
Wako Chemicals, USA), rabbit anti-GFAP (1:500; DAKO),
rat anti-CD3 (1:300; AbD Serotec). Secondary anti-
bodies used are as follows: Alexa Fluor-488 (1:200; Life
Technologies) and Cy3-conjugated donkey anti-rabbit or
anti-rat (1:200; Jackson ImmunoResearch). 4′,6-diamidino-
2-phenylindole (DAPI; 0.01 mg/ml) was used to visualize
nuclei. All images were acquired using a LSM7 Zeiss
confocal laser-scanner microscope (Zeiss, Göttingen,
Germany) and processed by NHI ImageJ software [8, 22].
Immunohistochemistry
A section every third (for a total of eight sections per
animal) throughout the rostro-caudal extent of the striatum
was selected for staining and examination. Freshly cut
30-μm serial sections, after blocking of nonspecific
staining with 10 % normal donkey serum, were incubated
overnight with a rabbit polyclonal antibody against parval-
bumin (PV) (1:1000; Immunological Science), then with a
biotinylated rabbit secondary antibody (1:500; Vector
Laboratories, Burlingame, CA, USA) for 1 h, and finally
with Extravidin (1:1000; SIGMA) for 1 h. Reaction was de-
veloped in a freshly prepared diaminobenzidine (DAB)/
H2O2 (DAB tablet, SIGMA). Sections were mounted on
glass slides and coverslipped under Eukitt.
Stereology
Quantitative observations were limited to the dorsal
striatum of the left hemisphere. Using the Stereo Inves-
tigator System (MicroBrightField Europe e.K., Magdeburg,
Germany) composed of a Zeiss Axioimager.M2 micro-
scope and MicroBrightField’s Stereo Investigator software
package, an optical fractionator, stereological design was
applied to obtain unbiased estimates of total PV+ cells.
Sampling grids and magnifications were adjusted to obtain
a relatively constant number of cells sampled and a coeffi-
cient of error (CE Gunderson) of ≤0.1. A tri-dimensional
optical dissector counting probe (x, y, z dimension of
200 × 200 × 25 μm, respectively) was applied. Counts were
performed using a ×20 objective.
Total number was estimated according to the following
formula:
N ¼ ∑Q 1=ssf  1=asf  1=tsf :
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where ΣQ represents the total number of neurons
counted in all optically sampled fields of the dorsal stri-
atum, ssf is the section sampling fraction, asf is the area
sampling fraction, and tsf is the thickness sampling
fraction.
Cell culture supernatant Luminex assay
The BV2 immortalized murine microglial cell line was
pre-treated for 1 h with siponimod 0.1 μM in dimethyl
sulfoxide (DMSO), before incubation with tumor necro-
sis factor (TNF; 200 U/ml; Milteny Biotec); control cells
received equal volume of DMSO (n = 3 per condition).
The 24-h conditioned media was assayed for IL-6 and
RANTES by Luminex assay, according to the manufac-
turer instructions (R&D systems). The plate was read on
a Luminex-200 instrument (Luminex Corp., Austin, TX).
Concentrations were calculated by using a standard
5P-logistic weighted curve generated for each target and
expressed as picograms per milliliter (pg/ml).
Statistical analysis
For each type of experiment, at least three mice per
group were employed. Throughout the text, “n” refers to
the number of animals, except for electrophysiology,
where it means the number of cells. Data were presented
as the mean ± S.E.M. The significance level was estab-
lished at p < 0.05. Statistical analysis was performed using
unpaired Student’s T test for comparisons between two
groups and non-parametric Mann-Whitney test, where
needed. Multiple comparisons were analyzed by one-way
ANOVA for independent measures followed by Tukey’s
HSD or Newman-Keuls.
Results
Intracerebroventricular injection of 0.45 μg/day siponimod
ameliorates clinical score of EAE mice without affecting
peripheral CD3+ cell count
In order to assess whether siponimod has direct neuro-
protective effects, the drug was delivered directly into
the brain by means of continuous intracerebroventricu-
lar infusion, starting 1 week before the induction of
EAE. During the acute phase of the disease, several bio-
chemical and electrophysiological analyses were performed
on both the peripheral and the CNS compartment (Fig. 1a,
timeline of the experimental design).
First, we tested three dosages of the drug (4.50, 0.450,
and 0.225 μg/day) for their possible impact on peripheral
T lymphocytes: siponimod is lipophilic and therefore
able to cross the blood brain barrier (BBB). At 18 dpi,
during the symptomatic phase of the disease, we counted
the total number of CD3+ lymphocytes in peripheral
blood samples of EAE mice receiving different dosages of
siponimod or vehicle: while the highest dose of siponimod
(4.5 μg/day; n = 3) elicited a strong reduction of T
lymphocytes in the blood of EAE mice compared to
EAE-vehicle mice (n = 4, p < 0.001; unpaired T test), the
intermediate (0.450 μg/day; n = 6) and the lowest
(0.225 μg/day; n = 4) dosages of siponimod induced a
slight and not significant drop in T lymphocyte counts
with respect to EAE-vehicle mice (unpaired T test; p >
0.05) (Fig. 1b). This result was consistent with siponi-
mod concentrations found in peripheral blood samples
(Fig. 1c): intracerebroventricular release of 4.5 μg/day
siponimod (n = 4) resulted in a high amount of the drug
in the peripheral blood (169.9 ± 31.49 nM), significantly
different from that measured in the blood of mice receiv-
ing 0.45 μg/day (n = 3) and 0.225 μg/day (n = 5; one-way
ANOVA p < 0.01; Tukey’s post hoc comparisons: 4.5 μg/
day vs 0.45 and 0.225 μg/day, p < 0.001). The concentra-
tions of siponimod detected in mice receiving 0.45 or
0.225 μg/day were detectable, but low (13 ± 4.7 nM and
6.6 ± 1.5 nM for the 0.45 and 0.225 μg/day groups, re-
spectively). These levels are not expected to have major
effects on peripheral lymphocytes in the majority of ani-
mals as confirmed by minor effects observed on periph-
eral lymphocyte count.
From a clinical point of view, such preventive and
CNS-directed treatment reduced motor disability associ-
ated to EAE in a dose-dependent manner (Fig. 1d). The
highest dose of siponimod used in this study fully inhib-
ited EAE development in treated mice compared to
EAE-vehicle (EAE-siponimod n = 5, EAE-vehicle n = 9;
from day 15 to 24 p < 0.001, non-parametric Mann-
Whitney). This result, together with that shown in
Fig. 1b, c, suggests that siponimod effects on peripheral
lymphocytes mediate its disease-modifying activity, when
administered at this daily concentration. Interestingly,
while the 0.450 μg/day (n = 6) and the 0.225 μg/day (n = 6)
doses exerted comparable effects on peripheral lympho-
cytes, only the former significantly ameliorated the disease
severity (p < 0.05, non-parametric Mann-Whitney) in
the dpi range of 21–24 of the disease compared to
EAE-vehicle (n = 9) (Fig. 1d).
Bringing together these data, we decided to carry out
the study using the 0.450 μg/day dose to better dissect
the neuroprotective action of siponimod.
Siponimod icv treatment reduces gray matter
inflammation in EAE mice
Activation of microglia and astrocytes are hallmarks of
both MS and EAE [23]. Both cell populations have been
demonstrated to sustain inflammation within the CNS
during autoimmune attack through antigen presentation
and/or cytokine/chemokine secretion [24–26]. Moreover,
we previously demonstrated that microglia and astroglia
together with infiltrating lymphocytes play a pivotal
role in inducing the synaptic alterations observed in
EAE brain [8–10, 15, 27].
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Fig. 1 Intracerebroventricular administration of 0.45 μg/day siponimod attenuates EAE motor deficits without inducing peripheral lymphocyte
depletion. a Schematic representation of the experimental design used in the study. Minipump implantation and siponimod/vehicle release preceded
the induction of EAE by 1 week. All examinations were performed on animals during the peak of the symptomatic phase of the disease 18–24 dpi,
both in the peripheral blood samples and in the striatum of the animals. b CD3+ lymphocytes were counted in the peripheral blood of EAE mice
receiving vehicle or different siponimod dosages: significant reduction was observed for the 4.5 μg/day dosage. Siponimod 4.5 μg/day vs
vehicle ##p < 0.01 unpaired T test; siponimod 0.45 μg/day vs vehicle p > 0.05 unpaired T test; siponimod 0.225 μg/day vs vehicle p > 0.05
unpaired T test. c Siponimod concentrations were determined in peripheral blood samples of EAE mice receiving intracerebroventricular
release of different siponimod dosages: the highest concentration (4.5 μg/day) used was significantly higher compared to both 0.450 μg/day
and 0.225 μg/day, while there were no statistically differences between the other two dosages. Tukey’s post hoc ***p < 0.001. d Representative
clinical course of EAE mice treated with three different siponimod dosages: EAE disease progression is strongly affected by 4.5 μg/day dosage
during the symptomatic phase of the disease and significantly attenuated by 0.45 μg/day concentration in the dpi range of 18–24. Daily
statistical significance was evaluated by non-parametric Mann-Whitney test
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We investigated by immunohistochemistry the effect
of siponimod on brain inflammatory reaction during EAE.
Coronal striatal slices were probed for the GFAP, a marker
upregulated during astrocyte activation. As depicted in
Fig. 2a, a substantial reduction of astrogliosis was ob-
served in EAE-siponimod striatum (green fluorescence for
GFAP staining, DAPI counterstaining in gray) compared
to EAE-vehicle. Qualitative data of confocal microscopy
images were confirmed by western blot analysis of protein
lysates from EAE-siponimod striatum compared to EAE-
vehicle striatum: GFAP levels, normalized to β-actin, were
reduced by 50 % in the striatum of EAE mice treated with
siponimod (Fig. 2b, b’; n = 5 for EAE-vehicle, n = 5 for
EAE-siponimod; p < 0.05, unpaired T test).
Microgliosis was assessed by immunofluorescence and
qPCR. As shown in Fig. 3a, the staining for the ionized
calcium binding adaptor protein-1 (IBA1), marker of
microglia/macrophage, is more pronounced in EAE-vehicle
than in EAE-siponimod striatum (red fluorescence,
counterstaining with DAPI in gray). Moreover, in the
same slices, icv treatment with siponimod reduced the
number of infiltrating lymphocytes compared to the
icv-vehicle control group (Fig. 3a, green fluorescence).
Quantitative analysis of IBA1 and CD3 transcripts by
qPCR confirms reduced microglia activation and
lymphocyte infiltration in the striatum of EAE mice re-
ceiving siponimod in comparison to EAE-vehicle (Fig. 3b;
n = 4 for EAE-vehicle, n = 5 for EAE-siponimod; p < 0.05,
unpaired T test).
In vitro application of siponimod reduces IL-6 and RANTES
release by TNF-treated microglial cells
Microglia have been clearly involved in neuronal damage
and T lymphocyte recruitment in the brain, by releasing
pro-inflammatory cytokines and chemokines, like IL-6
and RANTES, which have been implicated in EAE and
MS pathogenesis [28–32].
We tested the hypotheses that siponimod might reduce
microglia activation. To this aim, we used an in vitro
model of microglia activation. BV2 microglial cells were
Fig. 2 CNS-directed delivery of siponimod reduces astrogliosis in the EAE striatum. a Confocal microscopy images depict the striatum of EAE-vehicle
and siponimod mice stained for the astrocyte marker GFAP (green fluorescence, counterstained with DAPI, gray). Expression of GFAP is markedly
reduced in EAE-siponimod striatum compared to EAE-vehicle striatum (scale bar: 100 μm). The images are representative of stained sections
from three animals per groups from two immunizations. The panel in b shows western blot comparing EAE-siponimod and EAE-vehicle striatal
extracts probed for anti-GFAP antibody. Densitometric analysis of the bands in b’ reveals reduced GFAP content, relative to β-actin, in EAE-siponimod
lysates compared to EAE-vehicle. WB data are normalized to EAE-vehicle values. Unpaired T test was used for two-group analysis. Values are
means ± SEM, *p < 0.05
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pre-treated with 0.1 μM siponimod prior to 24-h stimula-
tion with TNF. By Luminex assay (Fig. 4a), we found that
siponimod prevented the release of IL-6 induced by TNF
stimulation of BV2 cells (one-way ANOVA: control cells
12.06 ± 0.55 pg/ml vs TNF 15.61 ± 0.40 pg/ml, p < 0.05
Tukey’s post hoc; TNF + siponimod 12.01 ± 0.21 pg/ml vs
TNF, p < 0.05 Tukey’s post hoc). Siponimod in the absence
of TNF did not alter the basal secretion of IL-6 (control
cells vs vehicle + siponimod 11.6 ± 1.11 pg/ml, p > 0.05
Tukey’s post hoc).
TNF induced a strong release of RANTES in cell
culture supernatant of BV2 cells (one-way ANOVA: con-
trol cells 596.2 ± 17.4 pg/ml vs TNF 1794 ± 33.65 pg/ml,
p < 0.001 Tukey’s post hoc; Fig. 4b). Siponimod reduced
Fig. 3 Attenuated microgliosis and reduced lymphocyte infiltration characterizes the striatum of EAE mice treated with siponimod. a Double
immunostaining of coronal striatal sections (in gray DAPI nuclei) showing expression of Iba1-positive microglia/macrophage cells (red) and of CD3
(green) in EAE-siponimod and EAE-vehicle mice. Only few lymphocytes could be detected in the striatum of mice treated with siponimod, and
microgliosis is visibly reduced in the same animals. Scale bar: 100 μm. b The levels of IBA1 and CD3 mRNA were quantified by qRT-PCR in the
striatum of EAE-siponimod versus EAE-vehicle mice using β-actin as internal control. The histogram shows that both IBA1 and CD3 mRNA
were significantly reduced in the striatum of siponimod-treated mice. Statistical significance was evaluated by unpaired T test: *p < 0.05
Fig. 4 In vitro siponimod application to activated BV2 microglial cell reduces IL-6 and RANTES release. BV2 cells were pre-treated with siponimod
prior to stimulation with TNF. The levels of secreted IL-6 (a) and RANTES (b) were measured by Luminex assay on collected media. Application of
siponimod to non-activated cells does not modulate the secretion of both molecules. Data were expressed as picograms per milliliter (pg/ml)
and were analyzed by one-way ANOVA, followed by Tukey’s post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001
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the amount of RANTES released by TNF-stimulated
cells (TNF vs siponimod + TNF 1621 ± 21.67 pg/ml, p <
0.01 Tukey’s post hoc; siponimod + TNF vs control p <
0.01 Tukey’s post hoc) (Fig. 4b). As for IL-6, siponimod
did not alter the release of RANTES by BV2 microglial
cells in the absence of TNF (control vs siponimod-TNF
698.4 ± 16.44 pg/ml, p > 0.05, Tukey’s post hoc).
Siponimod treatment recovers GABAergic transmission
alterations in EAE
We next asked whether siponimod might improve the syn-
aptic transmission alterations typical of EAE brains [11], by
recording both the glutamatergic and the GABAergic
currents from striatal MSNs.
We previously demonstrated that both the presynaptic
(frequency) and post-synaptic (kinetic) properties of the
spontaneous glutamatergic currents (sEPSCs) are altered
in the striatum of EAE mice during the acute phase of
the disease [15]. Here, we first investigated the effect
on sEPSCs after in vivo treatment with siponimod
0.45 μg/day on sEPSCs, by recording striatal slices in
the dpi range of 20–24. Siponimod did not correct neither
the kinetic parameters of rise time, decay time, and half
width (Fig. 5a–a”) nor the frequencies (Fig. 5a’–a”) of EAE
sEPSC (n = 8 for both groups; p > 0.05, unpaired T test for
all comparisons).
Conversely, siponimod icv treatment significantly ame-
liorated GABAergic defects in the striatum of EAE mice,
by increasing GABA frequencies, which are considerably
reduced in the symptomatic phase of the disease [6]. Sipo-
nimod restored normal values of frequency of spontan-
eous inhibitory post-synaptic currents (sIPSCs) (Fig. 5b, b’;
EAE-vehicle 0.61 ± 0.11 Hz, n = 10; EAE-siponimod:
1.52 ± 0.12 Hz, n = 8; p < 0.05, unpaired T test), suggest-
ing that siponimod might have neuroprotective effects
by preventing GABAergic transmission deficits.
Furthermore, in order to better explain the protective
role exerted by siponimod on GABA synapses, we incu-
bated EAE slices taken during the symptomatic phase
of the disease (20–25 dpi) with siponimod (1 μM) or
Fig. 5 Siponimod treatment corrects GABAergic defects in EAE striatum. a The glutamatergic transmission was recorded from MSNs of EAE-vehicle
and EAE-siponimod mice. The analysis of the increased kinetic properties (rise time, decay time, and half width) of sEPSCs showed that there were no
differences between the two groups (unpaired T test, p > 0.05). a’ The frequencies of the glutamatergic currents, increased in EAE striatum, were not
corrected by siponimod (unpaired T test, *p > 0.05). a” Electrophysiological traces representative of glutamatergic currents recorded from MSNs of
EAE-vehicle and EAE-siponimod mice. b Siponimod restores normal GABAergic frequencies in the striatum of acute phase EAE mice (unpaired
T test,*p < 0.05). b’ Electrophysiological traces representative of GABAergic currents recorded from MSNs of EAE-vehicle and EAE-siponimod
mice. c The frequencies of the GABAergic currents, reduced in EAE striatum, were completely rescued after 1 h of siponimod incubation in
EAE slices (unpaired T test, **p < 0.01)
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vehicle (DMSO) for 1 h. The in vitro treatment with sipo-
nimod was able to rescue the GABAergic impairment in-
duced by EAE (Fig. 5c). The sIPSC frequency was higher
in EAE-siponimod slices (1.47 ± 0.61 Hz, n = 8) in com-
parison to EAE untreated slices (0.78 ± 0.11 Hz; n = 8; p <
0.01, unpaired T test), reaching values indistinguishable
from control slices. These data support the idea that sipo-
nimod exerts its central protective role likely by reducing
resident immune cell activation.
Siponimod promotes PV+ interneuron survival
GABAergic interneurons, together with axon collaterals
from MSNs themselves, are the main source of GABA
inputs to striatal MSNs [33, 34]. The loss of parvalbumin-
positive (PV+) GABAergic interneurons together with the
noxious effects of pro-inflammatory cytokines has been pro-
posed as major determinant of the reduced GABAergic tone
in the striatum of EAE mice [6]. Therefore, we assessed
whether siponimod could prevent PV+ interneuron death in
the striatum of EAE mice.
To avoid possible interference of the damage caused
by the cannula inserted in the right lateral ventricle, we
performed unbiased stereological counts in the left
dorsal striatum of EAE mice. In Fig. 6a, there are repre-
sentative images of coronal slices stained with anti-
parvalbumin antibody. This experimental approach con-
firmed the reduction of the total number of PV+ neurons
in EAE-vehicle (1885 ± 117.7, n = 5) compared to control
CFA-vehicle striatum (2664 ± 156.6, n = 3) and, more
interestingly, showed a recovery induced by siponimod
(2293 ± 115.3, n = 5; one-way ANOVA p < 0.01; Newman-
Keuls post hoc comparisons: CFA-vehicle vs EAE-vehicle,
p < 0.01; CFA-vehicle vs EAE-siponimod, p > 0.05; EAE-
vehicle vs EAE-siponimod, p < 0.05; Fig. 6b).
These data indicate that siponimod prevents GABAergic
interneuron loss in the striatum of symptomatic EAE mice.
Discussion
Discovering drugs effective in progressive forms of MS
is a hard challenge for both researchers and physicians
Fig. 6 Brain infusion of siponimod promotes the survival of PV+ GABAergic interneurons during the course of EAE. a Low magnification images
(×5 objective) of coronal striatal sections from control CFA-vehicle, EAE-vehicle, and EAE-siponimod showing area selected for PV counting on
serial sections (dorsal striatum) and DAB-immunolabeled interneurons (scale bar: 200 μm): at high magnification, the density of PV+ cells is
visibly reduced in EAE-vehicle compared to that in CFA-vehicle with a partial recovery in EAE-siponimod slices. Yellow arrows indicate PV-labeled
cells (scale bar: 20 μm). b Histogram represents the quantitative stereological counts of PV+ cells performed on striatal slices: the intracerebroventricular
treatment with siponimod significantly increases the total number of PV+ cells in the dorsal left striatum of EAE mice. Data are expressed as mean ±
S.E.M. Statistical comparisons showed in the graph were calculated with Newman-Keuls post hoc: CFA-vehicle vs EAE-vehicle **p < 0.01; CFA-vehicle vs
EAE-siponimod p > 0.05; EAE-vehicle vs EAE-siponimod*p < 0.05
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working in the field of MS. Promoting neuroprotection
is a promising therapeutic strategy in the light of the
relevant contribution of neurodegeneration to MS
pathogenesis and progression [2]. GM damage, includ-
ing neuron and synaptic loss, is currently considered as
the major contributor to both cognitive impairment
and motor disability in MS patients [35, 36]. Recently,
it has been highlighted that inflammation-driven synap-
tic abnormalities are pathological hallmarks of both
EAE and MS brains: the sustained imbalance between
glutamatergic and GABAergic transmission, occurring
independently of demyelination and axonal loss, is sup-
posed to induce excitotoxic neurodegeneration [11]. Pre-
venting such inflammatory neurodegenerative mechanisms
is a novel and poorly explored therapeutic strategy.
In the present study, we investigated whether siponi-
mod could be neuroprotective in EAE mice, by limiting
striatal synaptopathy. Major findings of this study are
that the GABAergic transmission alterations typical of
the EAE striatum are rescued by siponimod treatment,
likely due to reduced local inflammatory reaction and to
increased survival of PV+ interneurons, which are the
main GABAergic input to MSNs. In an attempt to dis-
criminate the peripheral from the central effects of siponi-
mod, we used a direct and preventive CNS administration
of the drug, choosing the concentration of siponimod able
to ameliorate the disease severity, but with minimal im-
pact on blood lymphocyte count.
Adjusting the administration dose was our primary
goal to avoid that the observed beneficial effects could
be secondary to its peripheral immunomodulatory ac-
tion. In fact, by virtue of its lipophilic nature, siponimod
easily crosses the BBB reaching peripheral tissues. Not
surprisingly, the highest dosage (4.5 μg/day) tested in
this study resulted in significant blood exposure of sipo-
nimod and a strong reduction of T cells in the blood,
likely as a result of retention in lymph nodes, and com-
pletely prevented EAE development. The lower dosages
(0.45 and 0.225 μg/day) had both a minimal impact on
peripheral lymphocyte count with siponimod blood
levels reaching only low nanomolar range. Since the
0.225 μg/day dose had no effect on the clinical score, we
chose the 0.45 μg/day dosage due to its beneficial effect
on disease severity, even if this was limited to the peak
of the acute phase (20–24 dpi). However, since the clin-
ical symptoms are mainly due to lesions in the spinal
cord and since we expect a gradient of the compound
between the site of administration and the site of the
spinal cord lesions, a lack of strong clinical efficacy does
not rule out more potent effects at the proximity of the
administration site. Moreover, although we cannot ex-
clude any peripheral effect of siponimod, we might as-
sume that the observed recovery in clinical score could
be linked to central effects of this drug. Accordingly, this
treatment induced attenuation of microgliosis and astro-
gliosis with reduced number of infiltrating CD3+ lympho-
cytes in the striatum of EAE mice during the symptomatic
phase of the disease. A possible explanation for the low
number of infiltrating lymphocytes could be a reduced in-
flammatory reaction in the brain, caused by the preventive
and central treatment with siponimod, likely promoting a
different tissue distribution of T cells compared to EAE
untreated mice.
Indeed, CNS-resident cells, such as microglia, astroglia,
oligodendrocytes, and neurons, express sphingosine re-
ceptors, although with some differences in the receptor
subunit composition [21]. Most of the anti-inflammatory
effects of S1PR agonists, like fingolimod and siponimod,
in the CNS have been associated to their action on astro-
glia and microglia [37, 38]. Microglia activation occurs
early in the EAE brain and spinal cord, before the appear-
ance of motor deficits [25, 39, 40]. By secreting a number
of pro-inflammatory cytokines and chemotactic factors,
microglia are involved in the amplification of the
inflammatory reaction and the recruitment of monocyte-
blood-born cells and T cells into the brain. In our experi-
mental paradigm of preventive and central treatment with
siponimod, siponimod may prevent the chain of noxious
events triggered by microglia in the EAE brain, reducing
MOG-specific lymphocyte recruitment. To prove this
hypothesis, we used an in vitro simplification of the in
vivo experimental approach: we pre-treated microglial
cells with siponimod prior to activation with TNF. We
found that siponimod reduced microglial release of IL-6
and RANTES, some of the most relevant cytokines/
chemokines involved in EAE/MS pathogenesis [28–32].
Indeed, although IL-6 levels in the CSF of MS patients
have reported to be unaltered, likely indicating that IL-6 is
not a specific signature of the disease [41], it can be hy-
pothesized that this cytokine has a local role in the
modulation of the inflammatory reaction, since its ex-
pression was detected in glial cells of MS lesions [42].
Conversely, it is worth noting that RANTES levels have
been found increased in the CSF of MS patients [43]
and, most notably, they correlated with inflammation
and synaptic excitability [44].
We have recently demonstrated that inflammation causes
an imbalance between the glutamatergic and the
GABAergic transmission in the EAE striatum [6, 15].
Notably, such alterations are putative therapeutic targets,
and some drugs currently used in MS treatment have
already been found able to interfere with the chain of
events leading to such dysregulation [45–47]. Of note,
fingolimod, given systemically and starting the day of
immunization, was shown to strongly ameliorate clinical
deficits and to correct the glutamatergic transmission al-
terations of EAE striatum [45]. Here, we demonstrated
that siponimod rescued GABAergic transmission defects,
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without improving the glutamatergic transmission in MSNs.
Such differences between the results obtained with the
two S1P modulators probably stems from the way of
administration of the drug and the dose/drug exposure.
The oral delivery of fingolimod likely prevented T lym-
phocytes from migrating into the brain, thus explaining
the marked effect on disease progression and the excitatory
currents. Notably, even if in a small number, infiltrating T
cells, which have been highly involved in glutamatergic
alteration in the striatum of EAE mice [15] may be able
to affect excitatory transmission.
Furthermore, an acute exposure (1 h) of siponimod to
slices of EAE mice reproduced the same effect of the in vivo
treatment on GABA transmission, reinforcing the idea that
the compound may improve the inhibitory tone in the stri-
atum of EAE mice by interacting with resident immune cells.
In the present study, we observed that icv treatment with
siponimod recovered the frequencies of the sIPSCs in EAE
striatum. This specific impairment of the GABAergic
neurotransmission has been linked to inflammation, al-
though a selective cytokine or chemokine has not been
recognized, and to the reduced number of GABAergic
interneurons contacting MSNs in the EAE striatum [6].
The death of PV+ interneurons is a pathological hallmark
of both MS and EAE brains [6, 48], and the mechanisms
leading to such degeneration are still unknown. Inflamma-
tion is thought to play a role in this neuronal death, which
has been observed in other brain inflammatory conditions
[49] and in rodent chronic stress paradigms [50].
In the striatum of EAE mice, GABAergic defects occur
throughout the disease course [6]. In our study, we found
that siponimod promotes the survival of these neurons,
thus explaining the recovery of GABAergic neurotrans-
mission, in spite of the potentiated glutamatergic trans-
mission. Further studies are needed to dissect the
mechanisms of neuroprotection exerted by siponimod
on PV+ interneurons: other mechanisms involving neu-
roprotective factors, like the brain-derived neurotrophic
factor (BDNF), may be implied [51].
It is worth noting that reduced GABA concentrations
in the hippocampus and sensory-motor cortex have re-
cently been correlated with physical disability in progres-
sive MS patients [52]. This finding strongly corroborates
the role of the inflammatory synaptopathy in MS pro-
gression. Interestingly, in our study, the attenuation of
the motor symptoms of EAE mice treated with siponimod
was observed in the symptomatic phase of the disease in
connection to the improved tone of the GABAergic trans-
mission in the striatum, a subcortical brain area involved
in motor control [53] and compromised in MS [54].
Conclusions
In conclusion, the present investigation highlights a
neuroprotective activity of siponimod with respect to a
relevant feature of neurodegeneration affecting MS brains,
the reduced tone of GABAergic transmission.
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